VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

PHASE2TerminatedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Veltuzumab

administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection

Trial Locations (63)

44185

Nycomed Investigational Site, Guadalajara

44620

Nycomed Investigational Site, Guadalajara

64460

Nycomed Investigational Site, Monterrey

80020

Nycomed Investigational Site, Culiacán

82126

Nycomed Investigational Site, Mazatlán

85000

Nycomed Investigational Site, Ciudad Obregón

Unknown

Nycomed Investigational Site, La Mesa

Nycomed Investigational Site, Los Angeles

Nycomed Investigational Site, Upland

Nycomed Investigational Site, Aventura

Nycomed Investigational Site, Las Vegas

Nycomed Investigational Site, Charleston

Nycomed Investigational Site, Nashville

Nycomed Investigational Site, San Antonio

Nycomed Investigational Site, Calgary

Nycomed Investigational Site, Kitchener

Nycomed Investigational Site, Ottawa

Nycomed Investigational Site, St. Catharines

Nycomed Investigational Site, Toronto

Nycomed Investigational Site, Windsor

Nycomed Investigational Site, Saskatoon

Nycomed Investigational Site, Hlučín

Nycomed Investigational Site, Hostivice

Nycomed Investigational Site, Pilsen

Nycomed Investigational Site, Prague

Nycomed Investigational Site, Uherské Hradiště

Nycomed Investigational Site, Zlín

Nycomed Investigational Site, Bad Nauheim

Nycomed Investigational Site, Würzburg

Nycomed Investigational Site, Debrecen

Nycomed Investigational Site, Kecskemét

Nycomed Investigational Site, Kiskunhaias

Nycomed Investigational Site, Kistarcsa

Nycomed Investigational Site, Mezőkövesd

Nycomed Investigational Site, Székesfehérvár

Nycomed Investigational Site, Szolnok

Nycomed Investigational Site, Arenzano (GE)

Nycomed Investigational Site, Jesi (AN)

Nycomed Investigational Site, Massa

Nycomed Investigational Site, Valeggio S/M (VR)

Nycomed Investigational Site, Bialystok

Nycomed Investigational Site, Bydgoszcz

Nycomed Investigational Site, Lublin

Nycomed Investigational Site, Poznan

Nycomed Investigational Site, Sopot

Nycomed Investigational Site, Warsaw

Nycomed Investigational Site, Seville

Nycomed Investigational Site, Barakaldo

Nycomed Investigational Site, A Coruña

Nycomed Investigational Site, Ashford

Nycomed Investigational Site, Barnsley

C1015ABO

Nycomed Investigational Site, Caba

C1114AAH

Nycomed Investigational Site, Caba

C1419AHN

Nycomed Investigational Site, Caba

C1425DQK

Nycomed Investigational Site, Caba

C1425DTG

Nycomed Investigational Site, Caba

C1426AAL

Nycomed Investigational Site, Caba

X5016KEH

Nycomed Investigational Site, Córdoba

J5402DKL

Nycomed Investigational Site, San Juan

S3000FWO

Nycomed Investigational Site, Santa Fe

T4000AXL

Nycomed Investigational Site, San Miguel de Tucumán

06700

Nycomed Investigational Site, Distrito Federal

Nycomed Investigational Site, Distrito Federal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT01390545 - VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter